Search

Search Constraints

You searched for: Author/Creator Mallolas, Josep

Search Results

21. Impact of Prior Virological Failure and Nucleos(t)ide Genotypic Resistance Mutations on the Efficacy of Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir. Issue 5 (July 2015)

22. LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. (26th November 2018)

23. Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients. (April 2022)

24. Overview of SARS-CoV-2 infection in adults living with HIV. Issue 5 (May 2021)

25. Perception of quality of care using patient reported experience measures (PREMs) in a cohort of adults with HIV: A cross-sectional study. Issue 14 (7th April 2023)

26. Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection. Issue 5 (2nd November 2017)

27. Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre. (19th January 2022)

28. Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study. (5th May 2022)

29. Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Issue 11 (November 2021)

30. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. (1st August 2019)